🔬 Mechanism of Action

Ibrutinib forms a covalent bond with the BTK enzyme, inhibiting its activity. BTK plays a crucial role in B-cell receptor signaling, which is vital for the growth and survival of malignant B cells. By blocking this pathway, Ibruxen effectively impedes the progression of certain blood cancers.

📋 Indications

Ibruxen is indicated for the treatment of:

• Mantle Cell Lymphoma (MCL): For patients who have received at least one prior therapy.

• Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Including cases with 17p deletion. Medex

• Waldenström’s Macroglobulinemia (WM): A rare type of non-Hodgkin lymphoma. Medex

• Marginal Zone Lymphoma (MZL): For patients requiring systemic therapy after prior anti-CD20-based treatment.

💊 Dosage & Administration

• MCL and MZL: 560 mg (four 140 mg capsules) orally once daily.

• CLL/SLL and WM: 420 mg (three 140 mg capsules) orally once daily.

Capsules should be swallowed whole with water at the same time each day. Do not open, break, or chew the capsules.

⚠️ Precautions & Side Effects

Common side effects:

• Diarrhea

• Fatigue

• Musculoskeletal pain

• Upper respiratory tract infection

• Nausea

• Bruising

• Rash

• HypertensionMedEasy+2asmointernational.com+2magicinepharma.com+2

Serious risks:

• Hemorrhage

• Infections

• Cytopenias

• Atrial fibrillation

• Second primary malignancies

• Tumor lysis syndromeMedex

Patients should be monitored regularly for blood counts, signs of infection, and cardiac function. Use in pregnancy is not recommended due to potential fetal harm.

🏥 Manufacturer

Everest Pharmaceuticals Ltd. is a Bangladeshi pharmaceutical company specializing in oncology and other specialized therapeutic areas. Ibruxen is part of their commitment to providing affordable and effective cancer treatments.

Note: Always consult a registered healthcare professional before starting any new medication.